论文部分内容阅读
目的观察依达拉奉联合奥拉西坦治疗颅脑损伤的临床疗效。方法选取昌黎县人民医院60例颅脑损伤患者,将其随机分为2组:为治疗组和对照组,每组30例。治疗组在常规治疗的基础上,给予依达拉奉及奥拉西坦注射液治疗,对照组在常规治疗的基础上仅给予奥拉西坦注射液治疗。比较两组患者治疗后拉斯哥昏迷分度表(GCS)评分,Barthel指数,简易精神状态量表(MMSE)、神经功能缺损评分(NIHSS)的记分情况,评价2组总体疗效。结果治疗组在治疗7和14 d时的GCS评分分别为12.78±3.25和14.02±3.24,对照组分别为10.30±4.01和11.39±3.02,2组比较,差异均有统计学意义;Barthelr指数、MMSE和NIHSS记分治疗前后2组的差异均有统计学意义(均P<0.01)。结论依达拉奉联合奥拉西坦治疗颅脑损伤,具有理想的协同作用,能够明显改善患者神经功能缺损和预后,疗效显著。
Objective To observe the clinical efficacy of edaravone combined with oxiracetam in the treatment of craniocerebral injury. Methods Sixty patients with craniocerebral injury in Changli County People’s Hospital were selected and randomly divided into two groups: the treatment group and the control group, with 30 cases in each group. The treatment group was treated with edaravone and oxiracetam on the basis of routine treatment, while the control group was treated with oxiracetam only on the basis of routine treatment. The curative effect of the two groups was evaluated by comparing the scores of Laszog’s coma index (GCS), Barthel index, MMSE and NIHSS. Results The GCS scores of the treatment group were 12.78 ± 3.25 and 14.02 ± 3.24 at 7 and 14 days, respectively, and those in the control group were 10.30 ± 4.01 and 11.39 ± 3.02 respectively. There was significant difference between the two groups (P> 0.05). Barthelr index, MMSE And NIHSS scores before and after treatment were statistically significant (P <0.01). Conclusion Edaravone combined with oxiracetam in the treatment of craniocerebral injury has an ideal synergistic effect and can significantly improve the neurological deficit and prognosis of patients with significant curative effect.